key: cord-0751281-8df1im31
authors: Prakash, Ajay; Singh, Harvinder; Sarma, Phulen; Bhattacharyya, Anusuya; Dhibar, Deba Prasad; Balaini, Neeraj; Shree, Ritu; Goyal, Manoj; Modi, Manish; Medhi, Bikash
title: nCoV-2019 infection induced neurological outcome and manifestation, linking its historical ancestor SARS-CoV and MERS-CoV: a systematic review and meta-analysis
date: 2021-06-18
journal: Sci Rep
DOI: 10.1038/s41598-021-92188-x
sha: 37801f5b2c3804bdca091529c470583dcb283090
doc_id: 751281
cord_uid: 8df1im31

The first systematic review and meta-analysis to help clinician to identify early signs and symptoms of neurological manifestation in COVID-19 positive patients which will further help in early management of patients. Present systematic review and meta-analysis aimed to discuss the prevalence of neurological involvement of the 2019-nCoV patients and assess the symptomatic trend of events as compared to the 2002 “SARS” and 2012 “MERS” pandemics. The articles were systematically screened through several search engine and databases. The articles published or in preprint were included in the study till 15th May 2020. The systematic review done as per the published literatures which included 31 cross sectional, observational studies and case reports which revealed neurological signs and symptoms in SARS-COV-2 disease. For meta-analysis, we included 09 observational and cross-sectional studies which included COVID-19 positive patients and assessed the predominance of various neurological signs and symptoms in COVID-19 patients with relation to SARS-2002 and MERS-2012. Data was analyzed by using the “MedCalc” Statistical Software version 19.2.6 and reported as pooled prevalence. Standard I(2) test was used to analyze the heterogeneity. We have collected and screened about a total 2615articles, finally we have included 31articles for the systematic review and 09 for meta-analysis as per the inclusion/exclusion criteria. The analysis was made as per the prevalence rate of neurological symptoms in COVID-19 positive patients. The cumulative neurological outcome of SARS-2002 and MERS-2012 was assessed to get the trends which was further tried to correlate the events with the current pandemic. During the analysis severity and outcome of neurological manifestations range from simple headache to vague non-focal complaints to severe neurologic impairment associated with seizure or meningitis. Central and peripheral nervous system (CNS/PNS) manifestations were seen during the SARS-2002, MERS-2012 and COVID-19. However, none of the publication had primary or secondary objectives of searching neurological manifestations in the COVID-19 patients and the pathogenic mechanism which will subsequently strengthen the importance to start more prospective clinical trials. The prevalence of neurological signs and symptoms were taken as primary objective. Thereafter, the prevalence of each CNS/PNS symptoms was categorized and their prevalence studied. The selection of Bagheri et al., 2020 may be discussed because they have done the cross-sectional study with the neurological finding and correlated the data with prevalence of the COVID-19 positive patients. The proportion of patients presenting with neurological outcome and clinical/PCR positivity were done. We had searched and followed all the possible online/web source, still the data collection process may remain a limitation of work due to addition of several publications on COVID-19 every day. Due to lack of data of SARS-CoV and MERS-CoV, we have included the case reports, MERS and COVID-19 in CNS/PNS manifestations.

| (2021) 11:12888 | https://doi.org/10.1038/s41598-021-92188-x www.nature.com/scientificreports/ current systematic review and meta-analysis. Databases were systematically searched thoroughly and duplicates were independently screened by authors (DP, NB, AB and HM). In the next phase, articles were selected as per the titles/abstracts published and have the relevance as neurological outcome in COVID-19. For relevant articles, the full texts were obtained and evaluated as per neurological sign and symptoms in nCoV-2019 positive patients. BM, MM, MG and AP were consulted for any discrepancy or confusion. Four authors (HS, DP, RS and NB) have extracted data independently by using pre-tested Cochrane data extraction form.

Selection criteria. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) and Meta-analysis of Observational Studies in Epidemiology (MOOSE) were followed to analyze and report systematic review and meta-analysis (Fig. 1) . The registration of the review protocol was not previously done. The thorough search engine was used to collect all possible studies through Google scholar, MEDLINE (PubMed), EMBASE, OVID, Cochrane Central Library, CNKI, MedRixv and BioRixv and Scopus till June 5, 2020.

Statistical analysis. To analyze the differences in neurological impact, levels of anosmia/hyposmia, dyspnea, headache, headache and loss of consciousness were calculated according to the number of respondents per response to the number of total patients as categorical variables. Differences categorical variables were analyzed for proportion analysis by chi-square test. We used network analysis to correlate with the different pandemics )" was used to analyze the data. The fixed and random effect model were used to obtain pooled prevalence. Heterogeneity was investigated (standard χ 2 test) and represented as I 2 for the degree of inconsistency. Analyzed report showed both fixed effect and random effect model as necessary as an indication of the variability in the studies. The significant level set at p < 0.05 and prevalence range were represented as 95% CI. Publication bias in the selected study was evaluated by plotting the funnel plot and done the analysis accordingly.

Inclusion/exclusion criteria of studies Total 2615 articles were found in databases search and after removing duplicates, title and summary screening articles reduced to 1651, thereafter, a total of 1459 articles were excluded.

Full-text screening of the remaining 1156 articles was done. Among these studies, after full-text screening, a total of 31articles were included in the final review (Fig. 1) . Data collection and analysis 2,10-37 A total of 1651 articles were found after preliminary screening of the databases. After title and abstract screening, a total of 495 articles were excluded. Full-text screening of the remaining 1156 articles was done. Among these studies, after full-text screening, a total of 247 articles were included in the final review. The PRISMA flowchart 37 of the study is shown in Fig. 1 , 215 articles were excluded after fulltext screen (Not related to neurological manifestation = 32, Reports (incomplete data) = 78, In silico /in vitro study = 30, Management of SARS, MERS or COVID-19 = 55 incomplete epidemiological study = 20) . Details of studies with neurological manifestation in SARS-2002, MERS-2012 and COVID-19 summarized in Tables 1, 2 and 3.

A total of 09 studies (total 11,147 patients) reported occurrence of CNS-PNS combined symptoms in COVID-19 positive patients, the proportion was 48.278%, 45.718% by fixed and random effect size model, respectively. As there was significant heterogeneity 96.00%, (95% CI for I 2 94.08-97.29), we used random effect model. The forest plot is showed in Fig. 2a . No significant publication bias was seen (Fig. 2b) .

Overall prevalence of nervous system symptoms (CNS). A total of 08 studies (total 1078 patients) reported occurrence of CNS symptoms in COVID-19 positive patients, the proportion was 25.184% and 34.890% by fixed and random effect size model, respectively. As there was significant heterogeneity 95.32%, (95% CI for I 2 92.75-96.98) (P < 0.0001), we used random effect model. The forest plot is showed in Fig. 3a . Publication bias was seen, may be due to a smaller number of publications (Fig. 3b) .

Overall prevalence of peripheral nervous system (PNS) symptoms. A total of 08 studies (total 11,009 patients) reported occurrence of PNS symptoms in COVID-19 positive patients, the proportion 41.366% and 48.386% by random and fixed effect size model, respectively. As there was significant heterogeneity 98.82% (95% CI for I 2 98.43-99.11) (P < 0.0001), we used random effect model. The forest plot is showed in Fig. 4a . No significant publication bias was seen (Fig. 4b ).

Prevalence of ANOSMIA/HYPOSMIA as symptoms. A total of 3 studies (total 10,769 patients) reported occurrence of anosmia/hyposmia symptoms in COVID-19 positive patients, the proportion 48.547%, 37.270% by random and fixed effect size model, respectively. As there was significant heterogeneity 99.47% (95% CI for I 2 99.26-99.61), we used random effect model. The forest plot is showed in Fig. 5a . Publication bias was seen, may be due to very a smaller number of publications. (Fig. 5b) .

Overall prevalence of Myalgia. A total of 2 studies (total 77 patients) reported occurrence of Myalgia in COVID-19 positive patients, the proportion 21.279%, 19.994% by random and fixed effect size model, respectively. As there was significant heterogeneity 95.40% (95% CI for I 2 86.48-98.44), we used random effect model. The forest plot is showed in Fig. 6a . No significant publication bias was seen (Fig. 6b) .

Overall prevalence of fatigue. A total of 2 studies (total 135patients) reported occurrence of fatigue in COVID-19 positive patients, the proportion 24.674% and 30.810% by fixed and random effect size model, respectively. As there was significant heterogeneity 91.33% (95% CI for I 2 69.43-97.54) (P = 0.0007), we used random effect model. The forest plot is showed in Fig. 7a . No significant publication bias was seen (Fig. 7b) .

Overall prevalence of dyspnea. A total of 5 studies (total 731 patients) reported occurrence of Dyspnea symptoms in COVID-19 positive patients, the proportion 15.419% and 26.131% by fixed and random effect size model, respectively. As there was significant heterogeneity 95.48% (95% CI for I 2 92.01-97.44) (P < 0.0001), we used random effect model. The forest plot is showed in Fig. 8a . No significant publication bias was seen (Fig. 8b) .

Overall prevalence of headache. A total of 3 studies (total 629patients) reported occurrence of Headache in COVID-19 positive patients, the proportion 10.263%, 9.727% by random and fixed effect size model, respectively. As there was not significant heterogeneity 52.06% (95% CI for I 2 0.00-86.21), we used random effect model. The forest plot is showed in Fig. 9a . No significant publication bias was seen (Fig. 9b ). Fig. 10a . No significant publication bias was seen (Fig. 10b ). 

The present systematic review and meta-analysis revealed that the pattern of neurological manifestations of nCoV-2019 is related to the previous two ancestral pandemics i.e., SARS-2002 and MERS-2012. The main clinical manifestations of SARS and MERS were fever, chills, dry cough, and difficulty breathing which is related to nCoV-2019 symptoms as well. In moderate to severe cases, respiratory failure associated with multiple organ involvement may occur 32 . In addition, some of these patients developed neurological manifestations such as encephalitis, polyneuropathy, and aortic ischemic stroke 38 . Autopsy revealed overall deteriorating findings namely infiltration of monocytes and lymphocytes in the vessel wall, ischemic changes of neurons, demyelization of nerve fibers to the cerebral edema and meningeal vasodilation in patients.

Present systematic review and meta-analysis aimed to access the neurological manifestation of nCoV-2019 infection, which can further be classified into central nervous system (CNS) symptoms namely dizziness, headache, impaired consciousness, acute cerebrovascular disease, ataxia, and epilepsy and peripheral nervous system (PNS) symptoms like hypoplasia, hyposmia, neuralgia, and hypogeusia were studied 15, 46 .

Ina study by Hung et al. 30 showed SARS positivity in CSF sample of SARS-CoV and genome sequences of SARS in brain sample. MERS outbreak in 2012-13 also reported delirium, neuropathy and acute cerebrovascular disease 34, 36 whereas Saad et al. 20 reported confusion and seizures in 18 and 6 of the participants, respectively out of 70 MERS patients. Therefore, published literature showed the indication of neurotropism by the CoV family. Recent study by Moriguchi, et al. 21 , showed patients with SARS-CoV-2 suffered from meningitis/encephalitis which were confirmed by RT-PCR detection in cerebrospinal fluid.

The exact reason is unclear, however, few described in the literature are, development of focal meningitis/ encephalitis affecting the rhino-or gustatory-cortex or sub-cortical ascending/descending tracts in the CoV positive patients is one of the reasons which may be easily detect viral-RNA in the cerebrospinal fluid (CSF) of infected patients 15, 21 . In our network study meningitis/encephalitis, seizure and confusion were well connected to the SARS, MERS and COVID-19 pandemics.

PNS symptoms appeared due to involvement of peripheral nerves, including the cranial nerves which further associate to cranial nerves I, VII, IX, and X by SARS-CoV2 46 . Our study, reported common neurological signs and symptoms were dyspnea (15.419% and 26.131%), fatigue (24.674% and 30.810%), myalgia (19.994-21.279%), loss of consciousness (9.471-13.580%) and agnosia (37.270-48.547%). However, few case reports have reported even more severe neurological manifestations like seizure, GBS or meningitis/encephalopathy (Figs. 11, 12) . However, none of the studies observed the viral neurotropism but few authors have reported that the patients 39 . Therefore, it is very early to explain whether neurological dysfunction is due to direct viral injury or systemic disease. The other school of thought is that the neurotropism of CoV family occur mainly through two pathways, i.e., the hematogenous and retrograde route through respiratory infection. An experimental study showed that MERS-CoV tissue pantropism occurs after the viral entry into blood stream through endothelial infection in the choroid plexus 7, 22 .

High mortality and fast spread of the CoV-family viruses occurs due to the high fusion of these virus and rapid replication involving angiotensin converting enzyme-2 (ACE-2) receptor which is present throughout the vital organs 16 . Therefore, presence of ACE 2 receptor in brain is an important factor and link to study the neurological manifestations in 2019-nCoV infection. Patel AB, 2020 40 described that there is evidence for a major involvement of excessive brain ACE/Ang II/ AT-1R axis leading to increased activation of oxidative stress, apoptosis and neuroinflammation causing neurodegeneration and other brain disorders 44 . At last, the probable chance of neurological manifestation may be due to the cytokines overload and reduced immunity. Immuno-inflammation plays an important role in viral infection and which leads to the systemic inflammatory response syndrome (SIRS) 41 . In vitro study suggested that primary glial cells release large number of inflammatory cytokines namely 

The nCoV-2019 infection starts with mild flu-like symptoms to the late neurological manifestations in moderate to severely COIVD-19 positive patients. However, patients with comorbid conditions namely lung diseases, diabetes, obesity, hypertension, cardiac or kidney disease are more prone to exacerbation of disease or neurological manifestations or death. Further, studies suggested that the involvement of both peripheral and central nervous systems, also suggested of neurotropism of nCoV-2019. Therefore, we need more studies to conclude the neuro-invasion in brain and affected areas for the management of patients, worldwide.

In the present study, meta-analysis is restricted to the evaluations of observational and case report studies which was available at the earliest during the synthesis of the current study in the scientific community. Limited studies and rapid spreading nCoV-2019 pandemic restrict the evidence-based studies like randomized control trial (RCT)/double blind studies during the pandemics. Currently, there is other variant new strain is also identified and being studied. Therefore, there may chances of some new neurological symptoms to be reported. The good designed studied during pandemic is the major limitations of systematic analysis or meta-analysis study. 

Drug targets for corona virus: A systematic review

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: Estimation and application

COVID-19, SARS and MERS: A neurological perspective

COVID-19 coronavirus pandemic

COVID-19) pandemic

The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients

Frequent convulsive seizures in an adult patient with COVID-19: A case report. Iran Red Crescent Med J 22, e102828

Virus infections in the nervous system

Coincidence of COVID-19 epidemic and olfactory dysfunction outbreak

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Neurologic features in severe SARS-CoV-2 infection

Clinical characteristics of 36 non-survivors with COVID-19 in Wuhan

Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study

Neurological manifestations of hospitalized patients with COVID-19 in Wuhan, China: a retrospective case series study

Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan

Clinical features of 69 cases with coronavirus disease 2019 in Wuhan, China

Meningoencephalitis without respiratory failure in a young female patient with COVID-19 infection in Downtown Los Angeles

Spontaneous intracranial hemorrhage in a patient with Middle East respiratory syndrome corona virus Fahad M

Clinical aspects and outcomes of 70 patients with Middle East respiratory syndrome coronavirus infection: a singlecenter experience in Saudi Arabia

A first case of meningitis/encephalitis associated with SARS-Coronavirus-2

Central nervous system involvement by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)

Guillain-Barré syndrome during SARS-CoV-2 pandemic: A case report and review of recent literature

Guillain Barre syndrome associated with COVID-19 infection: A case report

De novo status epilepticus in patients with COVID-19

Guillain-Barré syndrome associated with SARS-CoV-2

Guillain-Barré syndrome associated with SARS-CoV-2 infection. ID Cases 20

Guillain-Barré syndrome associated with SARS-CoV-2 infection: Causality or coincidence?

Peripheral nerve disease in SARS: Report of a case

Detection of SARS coronavirus RNA in the cerebrospinal fluid of a patient with severe acute respiratory syndrome

Olfactory neuropathy in severe acute respiratory syndrome: Report of a case

Possible central nervous system infection by SARS coronavirus

Large artery ischaemic stroke in severe acute respiratory syndrome (SARS)

Neurological complications of middle east respiratory syndrome coronavirus: A report of two cases and review of the literature

Severe neurologic syndrome associated with Middle East respiratory syndrome corona virus (MERS-CoV)

Neurological complications during treatment of middle east respiratory syndrome

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration

Neuromuscular disorders in severe acute respiratory syndrome

Neurotropism of SARS-CoV 2: Mechanisms and manifestations

Role of the ACE2/Angiotensin 1-7 axis of the renin-angiotensin system in heart failure

COVID-19: Consider cytokine storm syndromes and immunosuppression

Neurologic alterations due to respiratory virus infections

Clearance effect of different blood purification techniques on parathyroid hormone in renal function failure patients on maintenance hemodialysis

Therapeutic options for the treatment of 2019-novel coronavirus: An evidence-based approach

Miller Fisher Syndrome and polyneuritis cranialis in COVID-19

Causes of hypogeusia/hyposmia in SARS-CoV2 infected patients

After the conception of idea of study AP and BM have designed the study with DP, MM and MG. Systematic databases were searched thoroughlyby authors H.M., D.P., P.S., N.B., P.S. and A.B. Articles were selected as per the titles/abstracts published and have the relevance as neurological outcome in COVID-19. For relevant articles, the full texts was obtained and evaluated as per neurological sign and symptoms in nCoV-19 infected patients. B.M., M.M., M.G. and A.P. were consulted for any discrepancy. Four authors (H.S., D.P., R.S. and N.B.) were extracted the data independently by using pre-tested Cochrane data extraction form. After independently verifying by B.M., M.M., M.G. and A.P., the data was entered into MedCalc software for review and interpretation. Disclaimer All statements in this systematic review, including its findings and conclusions, are solely those of the author's analysis and viewpoints.All statements in this systematic review, including its findings and conclusions, are solely those of the author's analysis and viewpoints.

The study was self-funded and did not receive any funding from any sources.

The authors declare no competing interests.

Correspondence and requests for materials should be addressed to B.M.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http:// creat iveco mmons. org/ licen ses/ by/4. 0/.